Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amy Wojciechowski"'
Autor:
Justin Jang Hann Chu, Jinhua Wang, Xuling Zhu, Nathanael S. Gray, Jianming Zhang, Priscilla L. Yang, Margaret J. Clark, Supanee Potisopon, Chandra V. Miduturu, Amy Wojciechowski, Jared D. Pitts, Aaron G. Schmidt
Publikováno v:
Cell Chemical Biology. 23:443-452
Summary Dengue virus infects more than 300 million people annually, yet there is no widely protective vaccine or drugs against the virus. Efforts to develop antivirals against classical targets such as the viral protease and polymerase have not yield
Autor:
Roxana E. Iacob, Wolfgang Jahnke, John R. Engen, Paul W. Manley, Guoxun Liu, Markus Warmuth, Badry Bursulaya, Gabriele Fendrich, Taebo Sim, Xianming Deng, Jianming Zhang, Francisco Adrian, Mohammad Azam, Barun Okram, Christine Dierks, Stephan Grzesiek, Navratna Vajpai, Yi Liu, Fangxian Sun, John T. Powers, Allen G. Li, Nathanael S. Gray, George Q. Daley, André Strauss, Sandra W. Cowan-Jacob, Gui Rong Guo, Qiang Ding, Tove Tuntland, Amy Wojciechowski, Yongmun Choi
Publikováno v:
Nature. 463:501-506
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor. Here, using solution NMR, X-ray crystallograp
Autor:
Dominic Cuerrier, Farisa Syeda, John R. Walker, Nathanael S. Gray, P.J. Finerty, Qingsong Liu, Sirano Dhe-Paganon, Amy Wojciechowski, Yongmun Choi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:4467-4470
The Eph family of receptor tyrosine kinases has drawn growing attention due to their role in regulating diverse biological phenomena. However, pharmacological interrogation of Eph kinase function has been hampered by a lack of potent and selective Ep
Autor:
Badry Bursulaya, Amy Wojciechowski, Xianming Deng, Qiang Ding, Francisco Adrian, Barun Okram, Yongmun Choi, Sandra W. Cowan-Jacob, Jianming Zhang, Nathanael S. Gray, Taebo Sim, Jianwei Che, Guobao Zhang, Gabriele Rummel
Publikováno v:
Journal of Medicinal Chemistry
Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2